HC Wainwright Reaffirms Buy Rating for BrainsWay (NASDAQ:BWAY)

BrainsWay (NASDAQ:BWAY)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 39.62% from the stock’s previous close.

BrainsWay Stock Performance

Shares of BWAY stock opened at $11.46 on Monday. The firm’s 50 day moving average price is $9.35 and its 200-day moving average price is $9.76. BrainsWay has a one year low of $5.67 and a one year high of $11.79. The firm has a market cap of $216.40 million, a P/E ratio of 114.61 and a beta of 1.32.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The firm had revenue of $11.54 million for the quarter, compared to analyst estimates of $11.45 million. As a group, research analysts predict that BrainsWay will post 0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC acquired a new stake in BrainsWay during the 4th quarter worth approximately $44,000. GAMMA Investing LLC lifted its holdings in BrainsWay by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company’s stock worth $89,000 after buying an additional 8,216 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in BrainsWay during the 1st quarter worth approximately $111,000. Trexquant Investment LP acquired a new stake in BrainsWay during the 1st quarter worth approximately $129,000. Finally, Sei Investments Co. acquired a new stake in BrainsWay during the 4th quarter worth approximately $149,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.